A prospective multicenter open-label randomized study to assess efficacy and safety of everolimus in combination with cyclosporine microemulsion versus everolimus without calcineurine inhibitor in combination with EC-MPS [enteric coated-mycophenolate sodium], in adult renal transplant patients in maintenance

Trial Profile

A prospective multicenter open-label randomized study to assess efficacy and safety of everolimus in combination with cyclosporine microemulsion versus everolimus without calcineurine inhibitor in combination with EC-MPS [enteric coated-mycophenolate sodium], in adult renal transplant patients in maintenance

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Ciclosporin; Corticosteroids
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Aug 2010 Primary endpoint 'Glomerular filtration rate' has been met.
    • 15 Aug 2010 Results presented at the 23rd International Congress of the Transplantation Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top